References
- Soliman EZ Prineas RJ, Go AS et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am. Heart J. 159, 1102–1107 (2010).
- Baber U Howard VJ, Halperin JL et al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: reasons for geographic and racial differences in stroke (REGARDS) study. Circ. Arrhythm. Electrophysiol. 4, 26–32 (2011).
- US Renal Data System. USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA (2006).
- Holden RM Harman GJ, Wang M, Holland D, Day AG. Major bleeding in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 3(1), 105–110 (2008).
- US Renal Data System. USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA (2005).
- Connolly SJ Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139–1151 (2009).
- Eikelboom JW Wallentin L, Connolly SJ et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 123, 2363–2372 (2011).
- Patel MR Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365, 883–891 (2011).
- Fox KA Piccini JP, Wojdyla D et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur. Heart J. 32, 2387–2394 (2011).
- Connolly SJ Eikelboom J, Joyner C et al. for the AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N. Engl. J. Med. 364, 806–817 (2011).
- Granger CB Alexander JH, McMurray JJ et al. for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365, 981–992 (2011).
- Eikelboom JW Connolly SJ, Gao P, Paolasso E, De Caterina R, Husted S. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J. Stroke Cerebrovasc. Dis. 21, 429–435 (2012).
- Lip GY Andreotti F, Fauchier L et al.; European Heart Rhythm Association. Bleeding risk assessment and management in atrial fibrillation patients. Executive summary of a position document from the european heart rhythm association [EHRA], endorsed by the european society of cardiology [ESC] working group on thrombosis. Thromb. Haemost. 106, 997–1011 (2011).
- Gage BF Yan Y, Milligan PE et al. Clinical classification schemes for predicting hemorrhage: results from the national registry of atrial fibrillation (NRAF). Am. Heart J. 151, 713–719 (2006).
- Fang MC Go AS, Chang Y et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study. J. Am. Coll. Cardiol. 58, 395–401 (2011).